Seki Dry Cough Syrup 200 Ml | Buy Online at Farmaclick

Seki dry cough syrup 200ml

AIFA PACKAGE LEAFLET

PHARMACOTHERAPEUTIC CATEGORY:

Cough suppressants, excluding combinations with expectorants.

ACTIVE INGREDIENTS:
10 mg coated tablets: cloperastine hydrochloride 10 mg.
35.4 mg/ml oral drops, suspension: 100 ml contain 3.54 g of cloperastine fendizoate equivalent to 1.8 g of cloperastine; 1 drop (equivalent to 0.05 ml) contains 1.8 mg of cloperastine fendizoate equivalent to 0.9 mg of cloperastine.
Children's 4.4 mg chewable tablets: cloperastine fendizoate 4.4 mg.

EXCIPIENTS:
10 mg coated tablets: microcrystalline cellulose, silica, talc, magnesium stearate, hypromellose, povidone, macrogol 4000, sucrose, magnesium carbonate, titanium dioxide, erythrosine (E127).
35.4 mg/ml oral drops, suspension: polyoxyethylene stearate, silica, methyl parahydroxybenzoate, sucrose, banana flavoring, purified water.
Children's 4.4 mg chewable tablets: sucrose, mannitol, microcrystalline cellulose, starch, methylcellulose, magnesium stearate, talc, strawberry essence.

INDICATIONS:
Cough suppressant.

CONTRAINDICATIONS/SIDE EFFECTS:
Hypersensitivity to the active ingredient or to any of the excipients.

DOSAGE:
Daily dose.
Adults.
Coated tablets: 2 tablets in the evening at bedtime; 1 tablet in the morning, 1 tablet in the afternoon, preferably between meals.
Drops: 30 drops in the evening before bedtime, 15 drops in the morning, 15 drops in the afternoon.
Children.
Chewable tablets.
Up to 7 years: 2 tablets in the evening at bedtime; one tablet in the morning; one tablet in the afternoon.
Over 7 years: 4-6 tablets in the evening at bedtime; 2-3 tablets in the morning; 2-3 tablets in the afternoon.
Drops: 14 drops in the evening before bedtime, 8 drops in the morning, 8 drops in the afternoon.
Under two years: proportionally smaller doses.

STORAGE:
Drops and chewable tablets: this medicinal product does not require any special storage conditions.
Coated tablets: store at a temperature not exceeding 25°C.

WARNINGS:
Sucrose: the tablets contain 48 mg of sucrose per dose; the chewable tablets contain approximately 36.8 mg of sucrose per dose; the drops contain approximately 140 mg of sucrose per ml.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine.
For diabetic subjects or those following low-calorie diets, it should be kept in mind that the preparation contains sugar.
The drops also contain parahydroxybenzoates (E218 and E216), which may cause allergic reactions, including delayed-type reactions.

INTERACTIONS:
No interaction studies have been conducted in humans.
Concomitant use with alcohol, antihistamines, anticholinergics, and sedatives is not recommended in either adult or pediatric patients.
It is not known whether the extent of the above-mentioned interactions in the pediatric age group is similar to that in adults.
There is no information regarding potential interactions between the drug and laboratory tests.
No information is available regarding the interaction of cloperastine with food; therefore, taking it during meals is not recommended.

UNDESIRABLE EFFECTS:
Frequency of undesirable effects: very common (>= 1/10); common (>= 1/100, < 1/10); uncommon (>= 1/1000, < 1/100); rare (>= 1/10000, < 1/1000); very rare (< 1/10000), not known.
Immune system disorders.
Not known: anaphylactic/anaphylactoid reaction.
Nervous system disorders.
Uncommon: drowsiness, dry mouth.
Skin and subcutaneous tissue disorders.
Not known: urticaria.
Pediatrics: clinical studies and post-marketing surveillance with cloperastine have not shown significant differences in the nature, frequency, severity, and reversibility of adverse reactions between the adult and pediatric populations.

PREGNANCY AND BREASTFEEDING:
No information is available regarding the use of Seki during pregnancy.
Although toxicity studies performed during pregnancy in animals did not show teratogenic activity or fetal toxicity, it is good practice not to take the drug during the first months of pregnancy and, thereafter, only in cases of actual need under the direct supervision of a physician.
It is not known whether the medicine and/or its metabolites are excreted in breast milk; since risk to the nursing infant cannot be excluded, it should not be used during breastfeeding.